Regulatory mechanisms in vascular injury and repair

Download files
Access & Terms of Use
open access
Copyright: Santiago, Fernando Santos
Altmetric
Abstract
Proliferation of SMC after vascular injury accounts for clinical conditions in transplant vasculopathy, in-stent restenosis and vein bypass graft failure. Vascular injury upregulates the expression of many transcription factors, two important ones are Yin yang-1 (YY-1) and early growth response-1 (Egr-1). The aims of this thesis were (1) to examine a possible mechanism by which a transcriptional repressor YY-1 inhibits SMC proliferation and (2) the development of a phospho-specifc antibody to a transcription activator, Egr-1 found to be a positive regulator of SMC proliferation. The results show that YY-1 inhibits p21WAF1/Cip1 transcription that perturbs the formation of p21WAF1/Cip1/cdk4/cyclin D1 complex thus blocking the downstream pRBSer249/Thr252 phosphorylation and expression of PCNA and TK-1. This inhibition was observed only in SMCs and not in ECs. Moreover, inhibition of endogenous YY-1 was performed to show the gain- and loss-of function of this transcription factor. YY-1 binds with Sp1 and prevents its occupancy of a Sp1 binding element in the p21WAF1/Cip1 promoter without YY-1 itself binding to the promoter. YY- 1 suppression of p21WAF1/Cip1 also involves p53 ubiquitination and proteasomal degradation. Further studies showed that overexpression of the first two-zinc finger region of YY-1 can inhibit smooth muscle cell proliferation and not ECs. This cell-type specific effect of YY-1 could be a potential tool in controlling SMC proliferation in drug eluting stent. The second part of this dissertation is the generation of phosphospecific antibody to Egr-1. Egr-1 controls a variety of genes implicated to SMC proliferation. Phosphorylation of Egr-1 can induce or repress the expression of its target gene depending on what type of kinase is involved. Preliminary data show that a phospho-specific antibody to Egr-1, pS26, can detect the Egr-1 phosphorylated protein from cell extract. Specificity of pS26 was determined also using slot blots of synthetic peptides and recombinant proteins, peptide blocking and phosphatase treatment. Further validation is needed to 6 fully confirm the specificity of this new phospho-specific antibody to Egr-1. A phospho-specific antibody to Egr-1 will serve as a tool to dissect mechanism by which this immediate early gene product exerts it control on fibroproliferative vasculopathies. The results generated by this thesis have added a new layer on the understanding of mechanism on inhibition of SMC proliferation and a generation of potential tool to dissect the mechanism of phosphorylation of a transcription factor implicated to SMC proliferative vasculopathy.
Persistent link to this record
Link to Publisher Version
Link to Open Access Version
Additional Link
Author(s)
Santiago, Fernando Santos
Supervisor(s)
Khachigian, Levon
Creator(s)
Editor(s)
Translator(s)
Curator(s)
Designer(s)
Arranger(s)
Composer(s)
Recordist(s)
Conference Proceedings Editor(s)
Other Contributor(s)
Corporate/Industry Contributor(s)
Publication Year
2012
Resource Type
Thesis
Degree Type
PhD Doctorate
UNSW Faculty
Files
download whole.pdf 1.24 MB Adobe Portable Document Format
Related dataset(s)